PharmaCyte Biotech Inc. (PMCB)
PharmaCyte Biotech Statistics
Share Statistics
PharmaCyte Biotech has 6.97M shares outstanding. The number of shares has increased by -17.68% in one year.
| Shares Outstanding | 6.97M |
| Shares Change (YoY) | -17.68% |
| Shares Change (QoQ) | -9.26% |
| Owned by Institutions (%) | 7.86% |
| Shares Floating | 6.23M |
| Failed to Deliver (FTD) Shares | 369.01K |
| FTD / Avg. Volume | 2.03K% |
Short Selling Information
The latest short interest is 52.64K, so 0.76% of the outstanding shares have been sold short.
| Short Interest | 52.64K |
| Short % of Shares Out | 0.76% |
| Short % of Float | 0.84% |
| Short Ratio (days to cover) | 1.09 |
Valuation Ratios
The PE ratio is 60.86 and the forward PE ratio is -4.24. PharmaCyte Biotech's PEG ratio is 0.08.
| PE Ratio | 60.86 |
| Forward PE | -4.24 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.51 |
| P/FCF Ratio | -9.44 |
| PEG Ratio | 0.08 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for PharmaCyte Biotech Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.8, with a Debt / Equity ratio of 0.
| Current Ratio | 6.8 |
| Quick Ratio | 6.8 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.01% and return on capital (ROIC) is -16.5%.
| Return on Equity (ROE) | 0.01% |
| Return on Assets (ROA) | 0.01% |
| Return on Capital (ROIC) | -16.5% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $166,881.5 |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -13.13% in the last 52 weeks. The beta is -0.25, so PharmaCyte Biotech's price volatility has been lower than the market average.
| Beta | -0.25 |
| 52-Week Price Change | -13.13% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 1.8 |
| Relative Strength Index (RSI) | 45.63 |
| Average Volume (20 Days) | 18.19K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -6.52M |
| Net Income | 333.76K |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.8 |
Balance Sheet
The company has 50.18M in cash and 0 in debt, giving a net cash position of 50.18M.
| Cash & Cash Equivalents | 50.18M |
| Total Debt | 0 |
| Net Cash | 50.18M |
| Retained Earnings | -115.63M |
| Total Assets | 55.1M |
| Working Capital | 16.56M |
Cash Flow
In the last 12 months, operating cash flow was -2.15M and capital expenditures 0, giving a free cash flow of -2.15M.
| Operating Cash Flow | -2.15M |
| Capital Expenditures | 0 |
| Free Cash Flow | -2.15M |
| FCF Per Share | -0.22 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PMCB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -104.65% |
| FCF Yield | -17.95% |
Analyst Forecast
Currently there are no analyst rating for PMCB.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 12, 2021. It was a backward split with a ratio of 1:1550.
| Last Split Date | Jul 12, 2021 |
| Split Type | backward |
| Split Ratio | 1:1550 |
Scores
| Altman Z-Score | -1.64 |
| Piotroski F-Score | 3 |